Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparability of Ipratropium Bromide HFA vs CFC in COPD
NCT02236169Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2000
- Primary completion
- Apr 2001
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ipratropium bromide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Amount of unchanged ipratropium excreted in the urine from 0 to 24 h after a single dose, Amount of unchanged ipratropium excreted in the urine within 1 hour at steady state and 1 more. Started Oct 2000; status: completed.
02
Drugs
ipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02236169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02236169.